VYTRUS BIOTECH EO -01 Asset Resilience Ratio

Latest as of December 2025: 0.00%

VYTRUS BIOTECH EO -01 asset resilience ratio. VYTRUS BIOTECH EO -01 (V5P) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See V5P days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of VYTRUS BIOTECH EO -01 (2021–2025)

Asset resilience ratio of VYTRUS BIOTECH EO -01 from 2021 to 2025. This chart shows how VYTRUS BIOTECH EO -01's Asset Resilience Ratio has changed over time. Read debt load of VYTRUS BIOTECH EO -01 for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down VYTRUS BIOTECH EO -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is VYTRUS BIOTECH EO -01's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: VYTRUS BIOTECH EO -01 maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

VYTRUS BIOTECH EO -01 Industry Peers by Asset Resilience Ratio

Compare VYTRUS BIOTECH EO -01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

VYTRUS BIOTECH EO -01 Asset Resilience Ratio by Year (2021–2025)

VYTRUS BIOTECH EO -01 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for VYTRUS BIOTECH EO -01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €522.14
≈ $610.44
€7.18 Million
≈ $8.40 Million
--
pp = percentage points

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$125.66 Million
€107.49 Million EUR
Market Cap Rank
#18161 Global
#1696 in Germany
Share Price
€14.30
Change (1 day)
+2.14%
52-Week Range
€5.85 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more